NASDAQ:GILD

Gilead Sciences News Headlines

$67.70
-1.07 (-1.56 %)
(As of 06/14/2021 10:47 AM ET)
Add
Compare
Today's Range
$67.66
$68.32
50-Day Range
$63.47
$69.35
52-Week Range
$56.56
$78.94
Volume117,518 shs
Average Volume7.95 million shs
Market Capitalization$84.91 billion
P/E Ratio294.36
Dividend Yield4.13%
Beta0.38

Gilead Sciences (NASDAQ GILD) News Headlines Today

SourceHeadline
Is it time for Americans to drop their infatuation with the PCR test? That’s what this COVID-19 testing expert thinksIs it time for Americans to drop their infatuation with the PCR test? That’s what this COVID-19 testing expert thinks
msn.com - June 14 at 9:09 AM
Longer-term Data for Kite’s Yescarta® in Relapsed or Refractory Follicular Lymphoma Demonstrate Substantial Survival Improvement Over Current Therapies in Comparative AnalysisLonger-term Data for Kite’s Yescarta® in Relapsed or Refractory Follicular Lymphoma Demonstrate Substantial Survival Improvement Over Current Therapies in Comparative Analysis
finance.yahoo.com - June 12 at 12:16 PM
Twist Bioscience (NASDAQ:TWST) vs. Gilead Sciences (NASDAQ:GILD) Head-To-Head ComparisonTwist Bioscience (NASDAQ:TWST) vs. Gilead Sciences (NASDAQ:GILD) Head-To-Head Comparison
americanbankingnews.com - June 12 at 7:10 AM
Gilead (GILD) Gets FDA Nod for Label Expansion of EpclusaGilead (GILD) Gets FDA Nod for Label Expansion of Epclusa
finance.yahoo.com - June 11 at 5:42 PM
Gilead’s Oral Epclusa Formulation Receives FDA Approval to Treat Hepatitis C in Children Aged 3 and AboveGilead’s Oral Epclusa Formulation Receives FDA Approval to Treat Hepatitis C in Children Aged 3 and Above
finance.yahoo.com - June 11 at 12:38 PM
Halftime Report Traders Share Their Thoughts On Gilead, IBM And More'Halftime Report' Traders Share Their Thoughts On Gilead, IBM And More
msn.com - June 10 at 8:08 PM
U.S. Food and Drug Administration Approves New Formulation of Epclusa®, Expanding Pediatric Indication to Treat Children Ages 3 and Older With Chronic Hepatitis CU.S. Food and Drug Administration Approves New Formulation of Epclusa®, Expanding Pediatric Indication to Treat Children Ages 3 and Older With Chronic Hepatitis C
finance.yahoo.com - June 10 at 8:08 PM
GILD July 30th Options Begin TradingGILD July 30th Options Begin Trading
nasdaq.com - June 10 at 3:08 PM
Whats Behind This Wild-Card Coronavirus Stock?What's Behind This Wild-Card Coronavirus Stock?
finance.yahoo.com - June 8 at 7:45 AM
The time for talk is over on health equity: HHSs Levine'The time for talk is over' on health equity: HHS's Levine
finance.yahoo.com - June 7 at 5:49 PM
The Petri Dish: Verilys new hire from FDA; Gileads call to the HillThe Petri Dish: Verily's new hire from FDA; Gilead's call to the Hill
bizjournals.com - June 4 at 9:38 PM
Noteworthy Friday Option Activity: GILD, VIAC, EANoteworthy Friday Option Activity: GILD, VIAC, EA
nasdaq.com - June 4 at 9:38 PM
Gilead Sciences, Inc Among Today’s Trending StocksGilead Sciences, Inc Among Today’s Trending Stocks
forbes.com - June 4 at 12:31 PM
Trodelvy® Demonstrates Superior Outcomes to Standard of Care in Second-Line Treatment of Metastatic Triple-Negative Breast Cancer in Phase 3 ASCENT StudyTrodelvy® Demonstrates Superior Outcomes to Standard of Care in Second-Line Treatment of Metastatic Triple-Negative Breast Cancer in Phase 3 ASCENT Study
finance.yahoo.com - June 4 at 11:37 AM
Gilead Sciences, Inc. (NASDAQ:GILD) Given Average Rating of "Buy" by BrokeragesGilead Sciences, Inc. (NASDAQ:GILD) Given Average Rating of "Buy" by Brokerages
americanbankingnews.com - June 4 at 8:20 AM
Helping provide the foundationHelping provide the foundation
bizjournals.com - June 3 at 10:40 PM
Interesting GILD Put And Call Options For July 23rdInteresting GILD Put And Call Options For July 23rd
nasdaq.com - June 3 at 5:39 PM
Big pharma scoops up major office space in North HillsBig pharma scoops up major office space in North Hills
bizjournals.com - June 3 at 7:38 AM
Russian court rejects U.S firms lawsuit over COVID-19 drug remdesivirRussian court rejects U.S firm's lawsuit over COVID-19 drug remdesivir
msn.com - May 28 at 10:54 AM
UPDATE 1-Russian court rejects U.S firms lawsuit over COVID-19 drug remdesivirUPDATE 1-Russian court rejects U.S firm's lawsuit over COVID-19 drug remdesivir
finance.yahoo.com - May 27 at 12:37 PM
New health-equity tracker launches for COVID-19 and beyondNew health-equity tracker launches for COVID-19 and beyond
finance.yahoo.com - May 26 at 9:31 AM
Russia ships remdesivir drug to India as part of humanitarian aidRussia ships remdesivir drug to India as part of humanitarian aid
finance.yahoo.com - May 25 at 2:48 PM
Can This Forgotten Coronavirus Stock Make You Rich?Can This Forgotten Coronavirus Stock Make You Rich?
finance.yahoo.com - May 25 at 2:48 PM
EU regulator backs extending approval for remdesivir for another yearEU regulator backs extending approval for remdesivir for another year
nasdaq.com - May 21 at 1:35 PM
EMA backs renewing conditional marketing approval for remdesivir in COVID-19 patientsEMA backs renewing conditional marketing approval for remdesivir in COVID-19 patients
nasdaq.com - May 21 at 8:35 AM
This Top Healthcare Dividend Stock Is a Bargain Right NowThis Top Healthcare Dividend Stock Is a Bargain Right Now
finance.yahoo.com - May 20 at 2:09 PM
GILD Named Top Dividend Stock of the Nasdaq 100 at Dividend Channel With 4.2% YieldGILD Named 'Top Dividend Stock of the Nasdaq 100' at Dividend Channel With 4.2% Yield
nasdaq.com - May 20 at 9:09 AM
Gilead-Kite Oncology to Present Transformative Science From Growing Portfolio at ASCO 2021Gilead-Kite Oncology to Present Transformative Science From Growing Portfolio at ASCO 2021
finance.yahoo.com - May 19 at 6:42 PM
Interesting GILD Put And Call Options For May 21stInteresting GILD Put And Call Options For May 21st
nasdaq.com - May 17 at 1:40 PM
Notable Friday Option Activity: ELY, GILD, OLEDNotable Friday Option Activity: ELY, GILD, OLED
nasdaq.com - May 14 at 6:24 PM
See Which Of The Latest 13F Filers Holds Gilead SciencesSee Which Of The Latest 13F Filers Holds Gilead Sciences
nasdaq.com - May 13 at 3:17 PM
Nasdaq 100 Movers: PDD, GILDNasdaq 100 Movers: PDD, GILD
nasdaq.com - May 10 at 2:52 PM
Noteworthy Friday Option Activity: GILD, LVS, CNoteworthy Friday Option Activity: GILD, LVS, C
nasdaq.com - May 7 at 2:53 PM
CDC’s projection of U.S. COVID-19 surge is a ‘crystal ball’: DoctorCDC’s projection of U.S. COVID-19 surge is a ‘crystal ball’: Doctor
finance.yahoo.com - May 5 at 3:23 PM
Gilead vs. Biogen: Which Biotech Stock is a Better Buy?Gilead vs. Biogen: Which Biotech Stock is a Better Buy?
stocknews.com - May 5 at 12:41 PM
Gilead Sciences: To Buy, Or Not To Buy - That Is The QuestionGilead Sciences: To Buy, Or Not To Buy - That Is The Question
seekingalpha.com - May 3 at 12:20 PM
Gilead Sciences, Inc. Just Missed EPS By 22%: Heres What Analysts Think Will Happen NextGilead Sciences, Inc. Just Missed EPS By 22%: Here's What Analysts Think Will Happen Next
nasdaq.com - May 2 at 12:38 PM
Gilead Sciences, Inc. Just Missed Earnings - But Analysts Have Updated Their ModelsGilead Sciences, Inc. Just Missed Earnings - But Analysts Have Updated Their Models
finance.yahoo.com - May 2 at 12:38 PM
Gileads Q1 Results Show Just How Much the Biotech Is Relying on Its COVID DrugGilead's Q1 Results Show Just How Much the Biotech Is Relying on Its COVID Drug
finance.yahoo.com - April 30 at 7:54 AM
Gilead Sciences (GILD) Q1 2021 Earnings Call TranscriptGilead Sciences (GILD) Q1 2021 Earnings Call Transcript
fool.com - April 30 at 12:45 AM
Gilead Sciences, Inc. 2021 Q1 - Results - Earnings Call PresentationGilead Sciences, Inc. 2021 Q1 - Results - Earnings Call Presentation
seekingalpha.com - April 29 at 9:19 PM
Gilead Sciences Inc. Q1 adjusted earnings Miss EstimatesGilead Sciences Inc. Q1 adjusted earnings Miss Estimates
markets.businessinsider.com - April 29 at 8:49 PM
Gilead HIV, hepatitis C sales dip, shares down 2.3%Gilead HIV, hepatitis C sales dip, shares down 2.3%
nasdaq.com - April 29 at 8:49 PM
Gilead Sciences Announces First Quarter 2021 Financial ResultsGilead Sciences Announces First Quarter 2021 Financial Results
finance.yahoo.com - April 29 at 8:49 PM
Gilead Sciences Announces Second Quarter 2021 DividendGilead Sciences Announces Second Quarter 2021 Dividend
finance.yahoo.com - April 29 at 8:49 PM
Gilead stock falls as COVID-19 drug sales dwindleGilead stock falls as COVID-19 drug sales dwindle
finance.yahoo.com - April 29 at 8:49 PM
Gilead 1st-quarter profit rises despite lower HIV drug salesGilead 1st-quarter profit rises despite lower HIV drug sales
finance.yahoo.com - April 29 at 8:49 PM
Gilead HIV, hepatitis C sales dip, shares down 2.6%Gilead HIV, hepatitis C sales dip, shares down 2.6%
finance.yahoo.com - April 29 at 8:49 PM
UPDATE 2-Gilead HIV, hepatitis C sales dip, shares down 2.6%UPDATE 2-Gilead HIV, hepatitis C sales dip, shares down 2.6%
finance.yahoo.com - April 29 at 8:49 PM
Gilead Stock Dives As Light HIV Drug Sales Lead To Quarterly MissGilead Stock Dives As Light HIV Drug Sales Lead To Quarterly Miss
finance.yahoo.com - April 29 at 8:49 PM
This page was last updated on 6/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.